Recurrent or Metastatic Clinical Trials

23 recruitingLast updated: June 18, 2026

There are 23 actively recruiting recurrent or metastatic clinical trials across 20 countries. Studies span Phase 2, Phase 1, Phase 3. Top locations include Guangzhou, Guangdong, China, Zhuhai, Guangdong, China, Barcelona, Spain. Updated daily from ClinicalTrials.gov.


Recurrent or Metastatic Trials at a Glance

23 actively recruiting trials for recurrent or metastatic are listed on ClinicalTrialsFinder across 6 cities in 20 countries. The largest study group is Phase 2 with 17 trials, with the heaviest enrollment activity in Guangzhou, Zhuhai, and Barcelona. Lead sponsors running recurrent or metastatic studies include Ming-Yuan Chen, Daiichi Sankyo, and Beijing Biotech.

Browse recurrent or metastatic trials by phase

Treatments under study

About Recurrent or Metastatic Clinical Trials

Looking for clinical trials for Recurrent or Metastatic? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Recurrent or Metastatic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Recurrent or Metastatic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 23 trials

Recruiting
Phase 1Phase 2

Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma

Recurrent or Metastatic Esophageal AdenocarcinomaBiomarker-selected CLDN18.2-positive and/or HER2-positive Disease
Beijing Biotech36 enrolled1 locationNCT07622940
Recruiting
Phase 1Phase 2

EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC

Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaBiomarker-positive EGFR/HER2- Expressing HNSCC
Beijing Biotech42 enrolled1 locationNCT07617805
Recruiting
Phase 2

Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma

Recurrent or Metastatic Nasopharyngeal Carcinoma
Ming-Yuan Chen33 enrolled1 locationNCT07581821
Recruiting
Phase 1

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

Recurrent or Metastatic Solid Tumors
Daiichi Sankyo76 enrolled26 locationsNCT07015697
Recruiting
Phase 1Phase 2

Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers

HPV 16+ Recurrent or Metastatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins24 enrolled1 locationNCT04713046
Recruiting
Phase 2

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

Recurrent or Metastatic Solid Tumors
Daiichi Sankyo520 enrolled119 locationsNCT06330064
Recruiting
Phase 3

A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Recurrent or Metastatic Nasopharyngeal Carcinoma
Shanghai Miracogen Inc.446 enrolled1 locationNCT06976190
Recruiting
Phase 1

Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors

Cervical CancerHNSCCHPV 16+ Recurrent or Metastatic Cancer
Therorna12 enrolled1 locationNCT07081984
Recruiting
Phase 1Phase 2

A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

Recurrent or Metastatic Nasopharyngeal Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.202 enrolled20 locationsNCT07258979
Recruiting
Phase 2

A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer

Recurrent or Metastatic Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd.60 enrolled2 locationsNCT07051486
Recruiting
Phase 2

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Recurrent or Metastatic Nasopharyngeal Carcinoma
Ming-Yuan Chen208 enrolled6 locationsNCT07070479
Recruiting
Phase 2

SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors

Locally Advanced, Recurrent or Metastatic Malignancies
Shenyang Sunshine Pharmaceutical Co., LTD.340 enrolled1 locationNCT07022002
Recruiting
Phase 2

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Shanghai Miracogen Inc.116 enrolled1 locationNCT04868162
Recruiting
Phase 1Phase 2

SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.100 enrolled1 locationNCT06859775
Recruiting
Phase 3

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
Shanghai JMT-Bio Inc.880 enrolled1 locationNCT05838066
Recruiting
Phase 2

Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N

Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Groupe Oncologie Radiotherapie Tete et Cou70 enrolled1 locationNCT06640725
Recruiting
Phase 2

Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC

Recurrent or Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University56 enrolled1 locationNCT06657690
Recruiting
Phase 2

Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC

Recurrent or Metastatic Nasopharyngeal Carcinoma
Ming-Yuan Chen32 enrolled1 locationNCT06472713
Recruiting
Phase 2

Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study

Advanced Non Small Cell Lung Cancer (NSCLC)Third-line and Beyond TherapyRecurrent or Metastatic Lung Cancer+1 more
Li-kun Chen32 enrolled1 locationNCT06728852
Recruiting
Phase 1

Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor

HER2-positive Recurrent or Metastatic Malignant Solid Tumor
Beijing Mabworks Biotech Co., Ltd.34 enrolled1 locationNCT03842085